Mechanism and experimental verification of "Polygoni Cuspidati Rhizoma et Radix-Ligustri Lucidi Fructus" combination in treatment of acute gouty arthritis based on network pharmacology.
10.19540/j.cnki.cjcmm.20211103.402
- Author:
Kang DU
1
;
Wei-Ding WANG
2
;
Bin HAN
3
;
Yi-Fei WANG
4
;
Zhi-Ping WANG
1
Author Information
1. Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University Guangzhou 510006, China Guangzhou (Jinan) Biomedical Research and Development Center Co., Ltd.,College of Life Science and Technology, Jinan University Guangzhou 510632, China.
2. Guangdong Provincial Engineering Center of Topical Precise Drug Delivery System, School of Pharmacy, Guangdong Pharmaceutical University Guangzhou 510006, China.
3. School of Traditional Chinese Medicine, Guangdong Pharmaceutical University Guangzhou 510006, China.
4. Guangzhou (Jinan) Biomedical Research and Development Center Co., Ltd.,College of Life Science and Technology, Jinan University Guangzhou 510632, China.
- Publication Type:Journal Article
- Keywords:
Polygoni Cuspidati Rhizoma et Radix-Ligustri Lucidi Fructus;
acute gouty arthritis;
experimental verification;
mechanism;
network pharmacology
- MeSH:
Animals;
Arthritis, Gouty/drug therapy*;
Drugs, Chinese Herbal/therapeutic use*;
Ligustrum;
Mice;
Network Pharmacology;
Rhizome
- From:
China Journal of Chinese Materia Medica
2022;47(6):1677-1686
- CountryChina
- Language:Chinese
-
Abstract:
Based on network pharmacology, the mechanism of Polygoni Cuspidati Rhizoma et Radix-Ligustri Lucidi Fructus(PL) combination against acute gouty arthritis(AGA) was explored and preliminarily verified by animal experiment. The chemical components and corresponding targets of PL were retrieved from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform(TCMSP). The active components with oral bioavailability(OB)≥30% and drug-likeness(DL)≥0.18 were screened based on literature, and the related protein targets were collected. Then the protein targets were standardized with the help of UniProt database. The AGA-related targets were searched from GeneCards, NCBI, and DrugBank. The common targets of the disease and the medicinals were yielded by FunRich V3, and the protein-protein interaction(PPI) network was constructed to screen the key targets, followed by Gene Ontology(GO) term enrichment analysis and Kyoto Encyclopedia of Genes and Genomes(KEGG) pathway enrichment analysis of the key targets. Afterwards, some of the key targets were verified by sodium urate crystal-induced AGA mouse model. A total of 25 active components and 287 targets of PL, 811 targets of AGA, and 88 common targets were screened out. PPI network analysis showed that tumor necrosis factor(TNF), interleukin-6(IL-6), and interleukin-1β(IL-1β) may be the core targets of PL in the treatment of AGA. The key targets were mainly involved in 566 GO terms(P<0.05), including multiple biological processes such as inflammatory response and immune response. Moreover, they were related to 116 KEGG pathways and these pathways were involved in inflammation and immunity, mainly including NOD-like receptor signaling pathway and TNF signaling pathway. Animal experiment confirmed that PL can alleviate ankle swelling, improve abnormal gait, and down-regulate the protein expression of TNF-α, IL-6, and IL-1β in AGA mice, indicating that PL can treat AGA through TNF-α, IL-6, and IL-1β and the feasibility of network pharmacology to predict drug targets. This study preliminarily discussed the key targets and biological signaling pathways involved in the treatment of AGA with PL combination, which reflected the multi-pathway and multi-target action characteristics of Chinese medicine. Moreover, this study laid a scientific basis for research on the treatment of AGA with PL combination, as well as the mechanism of action.
